Relationship between Cytochrome P450 2C19 * 2 Polymorphism and Stent Thrombosis following Percutaneous Coronary Intervention in Chinese Patients Receiving Clopidogrel

Abstract

This study investigated the relationship between the cytochrome P450 2C19 (CYP2C19) ^*2 polymorphism (681A) and definite stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel (75 mg/day, orally). The CYP2C19 ^*2 polymorphism status of 1738 Chinese patients with coronary artery disease was examined. The primary endpoint was the occurrence of definite ST during the 180-day follow-up period. The presence of at least one CYP2C19^*2 allele was significantly associated with increased ST risk (19 CYP2C19 ^*2/^*2 or ^*1/^*2 patients [2.4%] versus seven homozygous wild-type CYP2C19 ^*1/^*1 patients [0.75%]). The risk of definite ST was highest in patients with the CYP2C19 ^*2/^*2 genotype. The CYP2C19 ^*2 genotype is associated with an increased risk of definite ST following coronary stent placement among Chinese patients with coronary artery disease receiving clopidogrel.